Market Cap$126.58B
P/E32.04x
PEG Ratio1.96
Div yield—
Beta0.29
VRTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)2.58%
Price vs S&P 500 (4W)-0.82%
PEG Ratio1.96
VGM Score55.31
P/E Ratio (Annual)32.04x
VRTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $4.75 | $4.73 | -0.32%(-$0.02) | |
| Q1 2026 | $4.31 | $4.47 | +3.81%(+$0.16) | |
| Q4 2025 | $5.15 | $5.03 | -2.30%(-$0.12) | |
| Q3 2025 | $4.58 | $4.80 | +4.87%(+$0.22) | |
| Q2 2025 | $4.25 | $4.52 | +6.33%(+$0.27) |
VRTX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.10
4.05
4.06
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| BMYBristol-Myers Squibb Co. | B | B | B | 2.5x | 3.1% | 71.7% | — | $59.75 |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotech company with a dominant position in cystic fibrosis treatments (Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek) and a diversified pipeline including approved gene-editing therapy Casgevy for blood disorders and Journavx for acute pain. The company is also advancing cell therapies for type 1 diabetes and small-molecule programs targeting APOL1-mediated kidney disease.